S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-3.32%) $1.920
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Aktualne aktualizacje dla Bavarian Nordic A/S [BVNRY]

Giełda: OTC Sektor: Healthcare Branża: Biotechnology
Ostatnio aktualizowano26 bal. 2024 @ 18:20

1.82% $ 7.05

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 18:20):

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name...

Stats
Dzisiejszy wolumen 892.00
Średni wolumen 5 243.00
Kapitalizacja rynkowa 1.65B
EPS $0 ( 2024-03-07 )
Następna data zysków ( $0 ) 2024-05-14
Last Dividend $0.593 ( 2020-03-27 )
Next Dividend $0 ( N/A )
P/E 7.66
ATR14 $0 (0.00%)

Bavarian Nordic A/S Korelacja

10 Najbardziej pozytywne korelacje
10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Bavarian Nordic A/S Finanse

Annual 2023
Przychody: $7.06B
Zysk brutto: $4.52B (64.07 %)
EPS: $19.23
FY 2023
Przychody: $7.06B
Zysk brutto: $4.52B (64.07 %)
EPS: $19.23
FY 2023
Przychody: $0
Zysk brutto: $0 (0.00 %)
EPS: $0
FY 2022
Przychody: $3.15B
Zysk brutto: $1.70B (53.99 %)
EPS: $-4.93

Financial Reports:

No articles found.

Bavarian Nordic A/S Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Bavarian Nordic A/S Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.34 - Potential for dividend initiation, but uncertain (13.19%)
Information
First Dividend $0.593 2020-03-27
Last Dividend $0.593 2020-03-27
Next Dividend $0 N/A
Payout Date 2020-04-06
Next Payout Date N/A
# dividends 1 --
Total Paid Out $0.593 --
Avg. Dividend % Per Year 0.00% --
Score 2.27 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.34
Div. Directional Score 7.53 --
Next Divdend (Est)
(2024-04-28)
$0 Estimate 0.00 %
Dividend Stability
0.02 Very Bad
Dividend Score
2.27
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
TSGTY Ex Dividend Knight 2023-06-23 Annually 0 0.00%
JDVB Ex Dividend Knight 2023-07-27 Quarterly 0 0.00%
BMBN Ex Dividend Knight 2023-06-30 Semi-Annually 0 0.00%
RCBC Ex Dividend Junior 2023-07-31 Quarterly 0 0.00%
FABP Ex Dividend Knight 2023-07-31 Quarterly 0 0.00%
VNORP Ex Dividend Knight 2023-09-14 Quarterly 0 0.00%
LGRDY Ex Dividend Junior 2023-05-31 Annually 0 0.00%
CIBN Ex Dividend Knight 2023-09-14 Quarterly 0 0.00%
SEBC Ex Dividend Junior 2023-08-30 Quarterly 0 0.00%
GBOOY Ex Dividend Knight 2023-06-15 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.2091.5005.828.74[0 - 0.5]
returnOnAssetsTTM0.1031.2006.577.89[0 - 0.3]
returnOnEquityTTM0.1531.5009.4110.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM1.9380.8005.314.25[1 - 3]
quickRatioTTM1.3420.8006.815.45[0.8 - 2.5]
cashRatioTTM0.5301.5008.1710.00[0.2 - 2]
debtRatioTTM0.00430-1.5009.93-10.00[0 - 0.6]
interestCoverageTTM25.161.0001.7931.793[3 - 30]
operatingCashFlowPerShareTTM14.592.005.1410.00[0 - 30]
freeCashFlowPerShareTTM1.8492.009.0810.00[0 - 20]
debtEquityRatioTTM0.00597-1.5009.98-10.00[0 - 2.5]
grossProfitMarginTTM0.6521.0002.472.47[0.2 - 0.8]
operatingProfitMarginTTM0.2151.0007.707.70[0.1 - 0.6]
cashFlowToDebtRatioTTM18.151.00010.0010.00[0.2 - 2]
assetTurnoverTTM0.4920.800-0.0521-0.0416[0.5 - 2]
Total Score10.72

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM2.551.0009.840[1 - 100]
returnOnEquityTTM0.1532.509.6210.00[0.1 - 1.5]
freeCashFlowPerShareTTM1.8492.009.3810.00[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM14.592.005.1410.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.002281.500-3.320[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1581.0008.540[0.1 - 0.5]
Total Score4.34

Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej